Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy?

Core Viewpoint - Amicus Therapeutics (FOLD) is positioned as a strong investment opportunity due to its improving earnings outlook and positive analyst sentiment [1][2]. Earnings Estimate Revisions - Analysts are increasingly optimistic about Amicus Therapeutics' earnings prospects, leading to a rising trend in estimate revisions, which is expected to positively impact the stock price [2]. - The consensus earnings estimate for the current quarter is $0.12 per share, reflecting a year-over-year increase of +20.0%, with a 15% rise in estimates over the last 30 days [5]. - For the full year, the expected earnings are $0.31 per share, indicating a year-over-year change of +29.2%, with a 33.33% increase in consensus estimates due to positive revisions [6][7]. Zacks Rank and Performance - Amicus Therapeutics has achieved a Zacks Rank 2 (Buy), indicating favorable conditions for investment based on the positive estimate revisions [8]. - Historically, stocks with a Zacks Rank 1 (Strong Buy) and 2 (Buy) have significantly outperformed the S&P 500, suggesting strong potential for Amicus Therapeutics [8]. Stock Performance - The stock has gained 12.9% over the past four weeks, driven by solid estimate revisions and positive earnings growth prospects, making it a candidate for portfolio consideration [9].